Enlivex Therapeutics
ENLV
ENLV
21 hedge funds and large institutions have $1.32M invested in Enlivex Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
7% less capital invested
Capital invested by funds: $1.41M → $1.32M (-$98K)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Holders
21
Holding in Top 10
–
Calls
$1.21M
Puts
$207K
Top Buyers
| 1 | +$77.9K | |
| 2 | +$50.8K | |
| 3 | +$11.5K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.2K |
| 5 |
EE
EWG Elevate
Roseville,
California
|
+$394 |
Top Sellers
| 1 | -$24.8K | |
| 2 | -$18.5K | |
| 3 | -$14.9K | |
| 4 |
Goldman Sachs
New York
|
-$7.17K |
| 5 |
SIGI
Susquehanna International Group (Ireland)
Dublin,
Ireland
|
-$5.39K |